Clinical Trial Update: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of pembrolizumab plus lenvatinib for mucosal melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosal Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Melanoma Institute Australia | Conditions: Mucosal Melanoma | Phase 2 | Status: WITHDRAWN